In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the first large-scale longitudinal imaging study to evaluate BACE1 inhibition with micro-PET (positron emission tomography) in mouse models of Alzheimer’s disease. PET imaging has been established as an excellent identifier of the amyloid plaque and tau tangles that characterize Alzheimer’s disease. Now it is proving to be an effective way to gauge treatment effectiveness.

Philips recently announced that it acquired VitalHealth, a provider of cloud-based population health management solutions for the delivery of personalized care outside of the hospital, for example, in regional care networks. Headquartered in the Netherlands, VitalHealth’s products and services are being used by more than 100 healthcare networks in various countries including the United States, India, China, Sweden, Germany, Belgium and the Netherlands. The company was founded in 2006 by Mayo Clinic (U.S.) and Noaber Foundation (the Netherlands) and employs approximately 200 employees. Financial details of the transaction were not disclosed.

Median Technologies recently announced a research collaboration agreement with Xingtai People's Hospital, Xingtai City, China. Within the frame of the agreement, Median's MediScan image analysis technology will be used to conduct lung cancer screening programs organized under the aegis of Xingtai People's Hospital in Xingtai City. These programs are critically important to improving the health of the people of Xingtai City since the incidence of and mortality associated with lung cancer have increased dramatically in China and become a nationwide public health issue, giving rise to an increased burden on patients, healthcare professionals and society.

December 21, 2017 — Bay Labs, a medical technology company applying artificial intelligence (AI) to cardiovascular ...